Prognostic Factors Associated With Resectable Pulmonary Metastases From Colorectal Cancer

Llarena, Alberto Muñoz; Revilla, Sergio Carrera; Laborda, Aitziber Gil-Negrete; Ferrer, Joaquín Pac; Galíndez, Ramón Barceló; Vivanco, Guillermo López

doi:10.1016/s1579-2129(07)60076-7

Cited by 12 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metastatic palatine tonsil tumor generally occurs in lung [2] , breast [3] , stomach [4] , and kidney [5,6] . Distant metastasis of palatine tonsil tumor in liver [7] , brain [8] , and lung [9] is usually found in colorectal cancer patients following a surgical resection. Metastatic palatine tonsil tumor is often accompanied with synchronous lesions in other organs, a sign needing ag gressive palliative treatment [10] .…”

Section: Introductionmentioning

confidence: 99%

Ascending colon adenocarcinoma with tonsillar metastasis: A case report and review of the literature

Sheng

Zhang²,

Xu³

et al. 2008

WJG

View full text Add to dashboard Cite

Metastatic palatine tonsil cancer is extremely rare, with nearly 100 such tumors reported in the English literature. The prognosis of metastatic palatine tonsil cancer is poor. A 53-year-old man presented with painless left palatine tonsillar swelling and a cervical mass following right hemicolectomy for an ascending colon adenocarcinoma. Physical examination showed an ulcerated mass located on the upper pole of the left palatine tonsil. A punch biopsy was taken for histological examination which showed a moderatelydifferentiated adenocarcinoma. The patient was treated with palliative radiotherapy and chemotherapy. He was still alive when we wrote this paper. Our case shows that immunohistochemical diagnosis of metastatic palatine tonsil cancer is essential.

show abstract

Section: Introductionmentioning

confidence: 99%

Ascending colon adenocarcinoma with tonsillar metastasis: A case report and review of the literature

Sheng

Zhang²,

Xu³

et al. 2008

WJG

View full text Add to dashboard Cite

show abstract

“…Furthermore, none of the currently available trials evaluating this issue were designed to assess the impact of chemotherapy on outcomes as a primary outcome. Of these retrospective studies, seven [5][6][7][8][9][10][11] found no contribution of chemotherapy, one 12 had no detailed outcomes of chemotherapy, one 13 found an OS advantage of chemotherapy, two 14,16 found a non-significant trend towards higher five-year survival in patients receiving chemotherapy, and one 15 found a significant benefit in patients undergoing "adjuvant chemoradiotherapy" with a non-significant trend towards reduction in death at three years.In fact,there is no compelling evidence to advocate chemotherapy following PM,although it is widely practiced in clinical oncology. We observed no survival difference with respect to various chemotherapy regimens in the post-PM setting.…”

Section: Discussionmentioning

confidence: 99%

“…Several small retrospective trials evaluating the impact of chemotherapy following PM showed conflicting results. [5][6][7][8][9][10][11][12][13][14][15][16] Therefore, we conducted this retrospective study to investigate whether there is any difference in recurrence-free survival (RFS) or overall survival (OS) among patients treated with different cytotoxic regimens combined with or without bevacizumab (BEV) after PM from CRC. We also reviewed prognostic factors affecting survival following PM.…”

Section: Introductionmentioning

confidence: 99%

Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer.

Turan

Dane

Ünal

et al. 2013

JCO

View full text Add to dashboard Cite

Introduction:We investigated the impact of modern chemotherapy regimens and bevacizumab following pulmonary metastasectomy (PM) from metastatic colorectal cancer (CRC). Methods: A total of 122 consecutive patients who were curatively resected for pulmonary metastases of CRC in twelve oncology centers were retrospectively analysed between January 2000 and April 2012. Results: Of 122 patients, 14 did not receive any treatment following PM. The remaining 108 patients received fluoropyrimidine-based (n = 12), irinotecan-based (n = 56) and oxaliplatin-based (n = 40) chemotherapy combinations. Among these, 52 patients received bevacizumab (BEV) while 56 did not (NoBEV). Median recurrence-free survival (RFS) was 17 months and median overall survival (OS) has not been reached at a median follow-up of 25 months after PM. Three and five-year OS rates were 66% and 53%, respectively. RFS and OS were similar, irrespective of the chemotherapy regimen or BEV use. Positive pulmonary margin, KRAS mutation status, and previous liver metastasectomy were negative independent prognostic factors for RFS, while pathologically confirmed thoracic lymph node involvement was the only negative independent prognostic for OS in multivariate analysis. Conclusions: No significant RFS or OS difference was observed in respect to chemotherapy regimens with or without BEV in patients with pulmonary metastases of CRC following curative resection.

show abstract

“…There is more and more evidence that these methods could contribute significantly for assessment of the response from the therapy and for the planning of the treatment (56,57).…”

Section: Positron-emission Tomography (Pet) Andmentioning

confidence: 99%

Diagnostics of intrapulmonary metastases from colorectal cancer (literature survey)

Obretenov¹,

Georgieva²

2015

TJS

View full text Add to dashboard Cite

The colon cancer is on the first place as etiologic cause for performing pulmonary resection due to pulmonary metastases. The low effectiveness of chemotherapy in case of metastatic progression from colorectal carcinoma is established. Accordingly, the surgical resection is commonly accepted as the only potential therapeutic option. In favour of the good results from surgical treatment is the trend of earlier finding of pulmonary metastases. The metastases diagnostics has important meaning for differentiation from other lung diseases and for the choice of the therapeutic method. The benefits and disadvantages of non-invasive (chest X-ray, CT, lung perfusion scintigraphy, PET and PET/CT, tumor markers) and invasive (bronchoscopy, mediastinoscopy, VATS (video-assisted thoracic surgery, TTNB (trans-thoracic needle biopsy)) methods for diagnosis of intrapulmonary metastases are analyzed. Key words: colorectal cancer, pulmonary metastasesThere are different reports in the scientific literature about the incidence of colorectal carcinoma. According to some authors it is the third most often diagnosed cancer in the world (1-4). The data from P. J Villeneuve and R. S. Sundaresan (5) show that over one million new patients get sick from this insidious disease every year. H. Meulendeld at al. (6) report that 40% of the patients with colorectal carcinoma in Europe are over 75 years of age at the moment of first diagnosis and there are expectations that this number would significantly increase in the next two decades.The colorectal carcinoma in Bulgaria according to the data from 2012 for prevalence is on third place in men and on second place in women and represents 8.6% from all malignant diseases totally for both sexes. The registered new cases are 2772, and 52,7% of them in men. The diagnosis in 42,4% of the patients is set in advanced III and IV stages. The relative 5 -year survival in Bulgaria is 45,0% for men, 45,3% for women and 45,2% totally for both sexes. It is lower than the average for Europe-55,6%. (7). According to summed statistics A. ___________________________

show abstract

Prognostic Factors Associated With Resectable Pulmonary Metastases From Colorectal Cancer

Cited by 12 publications

References 29 publications

Ascending colon adenocarcinoma with tonsillar metastasis: A case report and review of the literature

Ascending colon adenocarcinoma with tonsillar metastasis: A case report and review of the literature

Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer.

Diagnostics of intrapulmonary metastases from colorectal cancer (literature survey)

Contact Info

Product

Resources

About